Polycystic ovary syndrome (PCOS) is a chronic hormonal and metabolic condition affecting roughly 8–13% of Canadian women of reproductive age. It is diagnosed using the Rotterdam criteria — two of three features (androgen excess, ovulatory dysfunction, polycystic ovarian morphology) after excluding other causes. See our full explainer for the complete clinical picture.

Has PCOS been renamed?

Yes. In 2026, the global medical consensus formally renamed PCOS to polyendocrine metabolic ovarian syndrome (PMOS). The condition, the diagnostic criteria, and the treatment framework are unchanged — only the name. Most Canadian charts still use PCOS during the transition period, and both terms refer to the same condition.

Why is PCOS belly fat so hard to lose?

PCOS-driven abdominal fat is caused by two intersecting mechanisms — insulin resistance (which drives fat storage into the visceral compartment) and androgen excess (which shifts body composition toward a more central distribution). Generic diet advice does not address either mechanism directly, which is why PCOS belly fat responds differently than ordinary weight gain.

How do I access PCOS care in Canada?

Start with your family physician, who can order the initial bloodwork (androgen panel, HbA1c, lipid panel) and refer to an OB-GYN or endocrinologist if needed. For ongoing, clinician-supervised metabolic management — the 12-month arc that most family physicians don't have bandwidth to deliver — Cloudcure's virtual program is designed specifically for that gap.

PCOS — Complete Canadian Resource Hub

Q: What is the most effective treatment for PCOS in Canada?

The 2023 International Evidence-Based PCOS Guideline recommends a lifestyle-first approach — sustained 5–10% weight loss, structured resistance training, dietary patterns that reduce refined-carbohydrate load, and sleep optimization. Prescription options — an insulin-sensitizing medication, newer medications that work through gut-hormone pathways, oral contraceptives, and medications that reduce androgen activity — may be layered in by a Canadian clinician when clinically appropriate, where lifestyle alone is insufficient or specific comorbidities indicate them.

About this hub

Polycystic ovary syndrome — now officially renamed polyendocrine metabolic ovarian syndrome (PMOS) — affects roughly 8–13% of Canadian women of reproductive age, making it one of the most common endocrine conditions they will encounter in their lifetimes. Despite its prevalence, PCOS is frequently under-diagnosed, under-treated, and under-explained. The typical Canadian woman waits years from symptom onset to diagnosis, and even after diagnosis, is often given limited guidance on what to actually do.

This hub organizes Cloudcure's full PCOS resource library in one place. Every article is built around the 2023 International Evidence-Based Guideline for the Assessment and Management of PCOS, the Society of Obstetricians and Gynaecologists of Canada (SOGC), and the Endocrine Society's PCOS clinical practice guideline.

Use the links below to navigate directly to the topic you need.

Polycystic ovary syndrome (PCOS), now also referred to as PMOS, is one of the most common hormonal and metabolic conditions among Canadian women, affecting roughly 8 to 13 percent of those of reproductive age, yet it is frequently underdiagnosed and underexplained. It is recognized through the Rotterdam criteria — two of three features: androgen excess, ovulatory dysfunction, and polycystic ovarian morphology — with insulin resistance at its core. This hub links Cloudcure's full PCOS library: what PCOS is and how it is diagnosed, why it drives stubborn belly fat, the evidence-based treatment options available in Canada, and what the rename to PMOS changes. Management centres on improving insulin sensitivity through nutrition, movement, sleep, and clinician-guided care.

Take the free 3-minute quiz

---

Start here — What PCOS actually is

What Is PCOS? A Canadian Guide

The clinical foundation. This article covers the full PCOS picture: the Rotterdam diagnostic criteria, the complete symptom map (hyperandrogenic, ovulatory, and metabolic), Canadian prevalence data from the SOGC, the difference between PCOS and PCOD, and the French-language term SOPK used in Quebec. If you are starting from scratch — or if someone you care about just received the diagnosis — start here.

Key topics: Rotterdam criteria · androgen excess · ovulatory dysfunction · polycystic ovarian morphology · Canadian prevalence · PCOD vs PCOS · SOPK (French term)

---

The 2026 rename — PCOS to PMOS

PCOS Is Now PMOS — What the 2026 Rename Means for Canadians

In 2026, a global medical consensus published in The Lancet and endorsed by the Endocrine Society formally renamed PCOS to polyendocrine metabolic ovarian syndrome (PMOS). The condition is unchanged. The diagnostic criteria are unchanged. The treatment framework is unchanged. But the name reflects a more accurate understanding of what the condition actually is — a systemic metabolic syndrome, not a purely ovarian or reproductive disorder.

This article explains the rename, why it happened, what it changes (and what it doesn't), and how it affects your Canadian chart, your prescriptions, and your conversations with your clinician.

Key topics: PMOS rename · Lancet consensus · Endocrine Society endorsement · Canadian chart transition · what changes for patients

---

Understanding the metabolic drivers

PCOS Belly Fat — A Canadian Doctor's Guide

The most common complaint among Canadian women with PCOS is not the irregular periods — it's the abdominal weight that doesn't respond to standard diet-and-exercise advice. This article explains exactly why that happens (the insulin resistance and androgen excess mechanisms) and what the 2023 international guideline shows actually moves it.

Evidence-ranked interventions include sustained 5–10% weight loss, resistance training, dietary pattern changes focused on reducing refined-carbohydrate load, and when appropriate, clinical options discussed with a licensed Canadian physician.

Key topics: PCOS belly fat mechanism · insulin resistance and androgens · the 5–10% weight loss target · diet evidence · resistance training · clinical options

---

Treatment options in Canada

PCOS Treatment in Canada — Evidence-Based Guide

A comprehensive review of PCOS treatment options available to Canadian women, organized by the evidence tier the 2023 international guideline assigns them. Covers lifestyle intervention, oral contraceptive pills (OCPs), medications that reduce androgen activity, insulin-sensitizing medication, newer medications that work through gut-hormone pathways, inositol supplementation, and what each option is actually indicated for versus marketed for.

Does not recommend specific medications or brands — that requires a clinical assessment by a licensed Canadian physician. Provides the information you need to have an informed conversation with your clinician.

Key topics: 2023 PCOS guideline treatment tiers · OCPs for PCOS · insulin-sensitizing medication for insulin resistance · gut-hormone-pathway prescription options · medications that reduce androgen activity · inositol evidence · lifestyle as first-line

---

PCOS across the lifespan — reproductive years to perimenopause

PCOS does not end at menopause. The 2023 international guideline explicitly addresses how the condition evolves through the reproductive years into perimenopause and beyond, and Canadian clinicians increasingly recognize it as a lifelong metabolic condition rather than a reproductive-phase syndrome.

Reproductive years

During the reproductive years, the most prominent features are typically androgen excess (acne, hirsutism, scalp hair thinning), irregular or absent periods, and challenges with fertility. Insulin resistance compounds all three: elevated insulin stimulates the ovaries to produce more androgens, worsening the hormonal picture. This is why weight management through nutrition and movement — not simply weight loss as an end in itself — is the foundation of the 2023 guideline's lifestyle-first approach. Even a modest 5–10% reduction in body weight has been shown to improve menstrual regularity, reduce androgen levels, and support ovulatory function in women with PCOS.

Our article What Is PCOS? A Canadian Guide covers the full reproductive-age picture, including the Rotterdam diagnostic criteria and what to expect from the initial Canadian workup.

Perimenopause and PCOS in midlife

The intersection of PCOS and perimenopause is underexplored and underdiagnosed. As estrogen levels shift during the perimenopausal transition, the metabolic burden of longstanding insulin resistance often becomes more visible. Canadian women with PCOS in their 40s may notice abdominal weight that accelerates, irregular cycles that they attribute solely to perimenopause, and worsening lipid profiles — all of which can be driven by the converging effects of PCOS and hormonal transition.

The 2023 International Evidence-Based PCOS Guideline notes that PCOS features can persist and evolve post-menopause, with cardiometabolic risk remaining elevated. Regular monitoring of fasting insulin, HbA1c, and lipid panels is recommended throughout the lifespan — not just during the reproductive years. Our article on perimenopause and weight gain in Canada explains how these two conditions overlap and what evidence-based strategies address both.

The PCOS-to-PMOS rename and lifespan framing

Part of the rationale behind the 2026 rename to polyendocrine metabolic ovarian syndrome (PMOS) was precisely this lifespan perspective. Framing it as "ovarian" had led many clinicians — and patients — to deprioritize management after the reproductive years ended. The new name reflects a systemic metabolic condition that warrants monitoring and management throughout life.

---

Screening tools useful for PCOS monitoring

Tracking insulin resistance, central fat, and body composition over time is part of responsible PCOS management. These free calculators are designed as clinical education aids and are PAAB-compliant (no drug names, no diagnostic claims):

HOMA-IR calculator — estimates insulin sensitivity from fasting glucose and insulin, the two markers most directly relevant to PCOS metabolic monitoring
Waist-to-height ratio calculator — a quick screen for central fat, which is disproportionately elevated in PCOS due to androgen-driven fat redistribution
BMI calculator — a starting point for population-level screening; best interpreted alongside waist circumference in PCOS because BMI misses fat distribution
TDEE calculator — helps set realistic energy targets to support the 5–10% weight-loss goal the 2023 guideline recommends as first-line

---

Hub citation sources

Teede HJ, et al. "Recommendations from the 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome." Journal of Clinical Endocrinology & Metabolism 2023;108(10):2447–69. The primary evidence source for all clinical claims in this hub. monash.edu/medicine/mchri/pcos/guideline

Society of Obstetricians and Gynaecologists of Canada (SOGC). PCOS clinical resources and position statements. Primary Canadian professional society for obstetrics and gynaecology; provides Canadian-specific guidance on hormonal conditions. sogc.org

Escobar-Morreale HF. "Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment." Nature Reviews Endocrinology 2018;14(5):270–84. A comprehensive review of PCOS pathophysiology including the insulin resistance and androgen excess mechanisms central to this hub's content.

---

How Cloudcure approaches PCOS care

Most Canadians with PCOS receive the diagnosis from their family physician or OB-GYN, are given general lifestyle guidance, and are left without a structured plan. The province pays for the diagnosis. It does not pay for the 12-month metabolic arc that addresses the insulin resistance, the androgen excess, and the downstream weight consequences.

Cloudcure's PCOS care program is specifically designed for the PCOS metabolic picture:

Baseline workup that includes HbA1c, fasting insulin, lipid panel, and a free androgen index calculation — so your clinician can see where your insulin resistance and hormonal picture actually sit before making any treatment recommendations.
A 12-month management arc anchored to the 5–10% sustained weight-loss target the 2023 international guideline supports, with monthly clinician check-ins and lab reviews at months 3, 6, and 12.
Nutrition coaching built around the dietary-pattern evidence from the international guideline — not a branded diet, not a supplement stack.
Coordination with your existing care team — your endocrinologist, OB-GYN, or family physician — when the clinical picture calls for it. We don't replace your specialist. We run the metabolic monitoring most specialists don't have bandwidth to run on a monthly basis.

The membership is HSA- and HCSA-eligible across major Canadian benefits providers. Eligibility takes about five minutes.

Start your eligibility check